View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2014	Mar. 17, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	ARCA Biopharma, Inc.
Entity Central Index Key	0000907654
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 30,003,945
Entity Common Stock, Shares Outstanding		21,198,411

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 15,354	$ 16,756
Other current assets	134	169
Total current assets	15,488	16,925
Property and equipment, net	36	29
Other assets	608	130
Total assets	16,132	17,084
Current liabilities:
Accounts payable	795	597
Accrued compensation and employee benefits	329	459
Accrued expenses and other liabilities	264	446
Total current liabilities	1,388	1,502
Deferred rent, net of current portion	3	1
Total liabilities	1,391	1,503
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding. Series A convertible preferred stock, $0.001 par value; 135,000 shares designated from authorized preferred stock; no shares issued or outstanding at December 31, 2014 and 2013
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2014 and 2013; 21,150,486 and 15,685,562 shares issued and outstanding at December 31, 2014 and 2013, respectively	21	16
Additional paid-in capital	99,342	90,498
Accumulated deficit	(84,622)	(74,933)
Total stockholders’ equity	14,741	15,581
Total liabilities and stockholders’ equity	$ 16,132	$ 17,084

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	21,150,486	15,685,562
Common stock, shares outstanding	21,150,486	15,685,562
Series A Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	135,000	135,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Costs and expenses:
Research and development	$ 5,625	$ 2,928
General and administrative	4,068	4,012
Total costs and expenses	9,693	6,940
Loss from operations	(9,693)	(6,940)
Interest and other income	7	5
Interest expense	(3)	(4)
Net loss and comprehensive loss	(9,689)	(6,939)
Less: Deemed preferred stock dividend		(2,026)
Net loss available to common stockholders	$ (9,689)	$ (8,965)
Net loss available to common stockholders per share:
Basic and diluted	$ (0.47)	$ (1.04)
Weighted average shares outstanding:
Basic and diluted	20,501,224	8,629,479

STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common stock	Additional Paid-in Capital	Accumulated Deficit	Series A Convertible Preferred Stock
Beginning Balance, shares at Dec. 31, 2012		2,660,315
Beginning Balance, value at Dec. 31, 2012	$ 2,907	$ 3	$ 70,898	$ (67,994)
Issuance of common stock for cash, net of offering costs, shares		521,066
Issuance of common stock for cash, net of offering costs	1,421		1,421
Adjustment for fractional shares		(64)
Issuance of common stock upon exercise of warrants for cash, shares		4,245
Issuance of common stock upon exercise of warrants for cash, value	12		12
Issuance of Series A convertible preferred stock, net of offering costs, shares					125,000
Issuance of Series A convertible preferred stock, net of offering costs	17,917		17,917
Deemed preferred stock dividend for beneficial conversion feature	2,026		2,026
Less: Deemed preferred stock dividend	(2,026)		(2,026)
Conversion of preferred stock, shares		12,500,000			(125,000)
Conversion of preferred stock	(20)	$ 13	(33)
Share-based compensation	283		283
Net loss	(6,939)			(6,939)
Ending Balance, shares at Dec. 31, 2013		15,685,562
Ending Balance, value at Dec. 31, 2013	15,581	$ 16	90,498	(74,933)
Issuance of common stock for cash, net of offering costs, shares		5,116,228
Issuance of common stock for cash, net of offering costs	7,866	$ 5	7,861
Issuance of common stock upon exercise of warrants for cash, shares		209,025
Issuance of common stock upon exercise of warrants for cash, value	338		338
Share-based compensation	647		647
Net loss	(9,689)			(9,689)
Ending Balance, shares at Dec. 31, 2014		21,150,486
Ending Balance, value at Dec. 31, 2014	14,741	$ 21	99,342	$ (84,622)
Issuance of common stock upon vesting of Restricted Stock Awards, shares		139,671
Issuance of common stock upon vesting of Restricted Stock Awards, value	$ (2)		$ (2)

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (9,689)	$ (6,939)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12	26
Amortization of deferred charges	67
Share-based compensation	647	283
Change in operating assets and liabilities:
Other current assets	214	130
Other assets	(545)	14
Accounts payable	198	532
Accrued compensation and employee benefits	(130)	356
Accrued expenses and other liabilities	(182)	325
Other	2	(15)
Net cash used in operating activities	(9,406)	(5,288)
Cash flows from investing activities:
Purchase of property and equipment	(19)	(32)
Net cash used in investing activities	(19)	(32)
Cash flows from financing activities:
Proceeds from the issuance of preferred stock		20,000
Proceeds from the issuance of common stock	9,038	1,741
Repayment of principal on vendor finance agreement	(179)	(174)
Net cash provided by financing activities	8,023	19,156
Net (decrease) increase in cash and cash equivalents	(1,402)	13,836
Cash and cash equivalents, beginning of period	16,756	2,920
Cash and cash equivalents, end of period	15,354	16,756
Supplemental cash flow information:
Interest paid	3	3
Preferred Stock
Cash flows from financing activities:
Offering costs		(2,083)
Common stock
Cash flows from financing activities:
Offering costs	$ (836)	$ (328)

The Company and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

The Company and Summary of Significant Accounting Policies

(1) The Company and Summary of Significant Accounting Policies

Description of Business

ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Westminster, Colorado. On January 27, 2009, the Company completed a business combination, or the Merger, with ARCA Colorado in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September 24, 2008, and amended on October 28, 2008, in which a wholly-owned subsidiary of Nuvelo, Inc. (Nuvelo) merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. The business combination was treated as a reverse merger for accounting purposes, and ARCA Colorado was the accounting acquirer, and the entity formerly known as Nuvelo, Inc. was the acquired company.

The Company is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, Gencaro™ (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator that ARCA is evaluating in a clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. The Company has identified common genetic variations in receptors in the cardiovascular system that it believes interact with Gencaro’s pharmacology and may predict patient response to the drug.

The Company is testing this hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. The AF indication for Gencaro was chosen based on prior clinical data from the previously conducted Phase 3 heart failure (HF) trial of Gencaro in 2,708 HF patients, or the BEST trial, which suggested that Gencaro may be successful in reducing or preventing AF. GENETIC-AF is a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator in HFREF patients with a current or recent history of paroxysmal (AF episodes lasting 7 days or less) or persistent AF and having a beta-1 389 arginine homozygous genotype, the genotype the Company believes responds most favorably to Gencaro. The primary endpoint of GENETIC-AF is time to recurrent symptomatic AF/atrial flutter (AFL) or all-cause mortality.

ARCA has created an adaptive design for GENETIC-AF. The Company is seeking to enroll approximately 200 HFREF patients in the Phase 2B portion of the study. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and enroll an additional 420 patients. The DSMB will make their recommendation based on analysis of certain trial data after 200 patients have completed 24 weeks of follow-up, the period for measuring the trial’s primary end-point. The DSMB interim analysis will focus on available data regarding the primary endpoint, AF/AFL event rates, AF burden, and safety. Should the DSMB interim analysis conclude the data is consistent with the pre-trial statistical assumptions and indicates potential for achieving statistical significance for the Phase 3 endpoint, the DSMB may recommend that the study proceed to Phase 3. The DSMB may also recommend changes to the study design before potentially proceeding to Phase 3, or it may recommend that the study not proceed to Phase 3. The Company, in consultation with the trial’s Steering Committee and the DSMB, will make the final determination on the trial’s development steps. The Company believes the Phase 2B enrollment of 200 patients could be completed by the end of 2016, with the DSMB interim analysis finishing in the first half of 2017.

To complete both phases of the GENETIC-AF clinical trial and submit for FDA approval, the Company will need to raise additional capital. If the Company is unable to obtain additional funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations.

Liquidity and Going Concern

The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. The Company has historically funded its operations through issuances of common and preferred stock.

During 2013, the Company raised approximately $19.3 million, net of offering costs, through sales of its convertible preferred stock and common stock and warrants. In February 2014, the Company completed a public equity offering raising approximately $7.9 million in net proceeds to provide additional funds for the Phase 2B/3 GENETIC-AF trial and the Company’s ongoing operations. The Company is enrolling patients in the Phase 2B portion of the GENETIC-AF trial, and the Company anticipates that its current cash and cash equivalents will be sufficient to fund its operations, at its projected cost structure, through the end of 2015. However, in light of the significant uncertainties regarding clinical development timelines and costs for developing drugs such as Gencaro, the Company expects to need to raise additional capital to finance the completion of GENETIC-AF and the Company’s ongoing operations. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or operations.

The Company’s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:

•	progress of GENETIC-AF, including enrollment and any data that may become available;

•	the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;

•	the market price of the Company’s stock and the availability and cost of additional equity capital;

•	the Company’s ability to retain the listing of its common stock on the Nasdaq Capital Market;

•	general economic and industry conditions affecting the availability and cost of capital;

•	the Company’s ability to control costs associated with its operations;

•	the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

•	the terms and conditions of the Company’s existing collaborative and licensing agreements.

The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company’s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company’s capital stock and could contain covenants that would restrict the Company’s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.

The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. These financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.

On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.

Reverse Stock Split

On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of our financial position, results of operations and cash flows for the periods presented. Our management performed an evaluation of our activities through the date of filing of this Annual Report on Form 10-K, and concluded that there are no subsequent events, except for the notice from NASDAQ disclosed in Note 1 to these financial statements.

Recent Accounting Pronouncements

In June 2014, the FASB issued FASB Accounting Standards Update (“ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation which removes Topic 915 from the FASB Accounting Standards Codification and removes from GAAP the concept of a development stage entity along with the associated incremental financial reporting requirements for development stage entities. The ASU is effective for fiscal years beginning after December 15, 2014, with early adoption being permitted for annual or interim periods for which financial statements have not been issued. The Company adopted this guidance as of June 30, 2014 and as a result, removed references to being a development stage entity and inception-to-date results from these financial statements.

In August 2014, the FASB issued FASB Accounting Standards Update (“ASU No. 2014-15”), Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU No. 2014-15 will be effective for fiscal years and interim periods ending after December 15, 2016, with early adoption being permitted for annual and interim periods for which financial statements have not been issued. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity’s ability to continue as a going concern within one year of the date that the financial statements are issued. The significant uncertainties surrounding the clinical development timelines and costs and the need to raise a significant amount of capital raises substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company does not expect a significant impact on the financial position, results of operations or disclosures upon adoption of this guidance.

Accounting Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company bases estimates on various assumptions that are believed to be reasonable under the circumstances. The Company believes significant judgment was involved in estimating the clinical trial accruals, and in estimating other accrued liabilities, stock-based compensation, and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.

Cash Equivalents

Cash equivalents generally consist of money market funds and debt securities with maturities of 90 days or less at the time of purchase. The Company invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.

The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of property and equipment is depreciated using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Property and equipment acquired in the Merger were recorded at the estimated fair value as of the date of the Merger, and are subsequently depreciated using the straight-line method over the estimated remaining useful lives of the related assets.

Accrued Expenses

As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company’s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.

Segments

The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.

Research and Development

Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.

Costs related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations, or CROs, clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre-approval of any changes in scope of the services to be performed. Certain significant vendors may also provide an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.

In accordance with certain research and development agreements, we are obligated to make certain upfront payments upon execution of the agreement. We record these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. We evaluate on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.

Stock-Based Compensation

The Company’s stock-based compensation cost recognized is based on the estimated grant date fair value. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.

Income Taxes

The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized. The Company has recorded a valuation allowance against all of its deferred tax assets, as management has concluded that it is more likely than not that the net deferred tax asset will not be realized through future taxable income, based primarily on the Company’s history of operating losses. The Company has not performed an Internal Revenue Code Section 382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited.

Net Loss Per Share

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Net Loss Per Share

(2) Net Loss Per Share

The Company calculates basic earnings per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted earnings per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company’s potentially dilutive shares include stock options, restricted stock units and warrants for common stock.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows:

	Years Ended December 31,
	2014			2013
(In thousands, except shares and per share data)
Net loss	$	(9,689	)	$	(6,939	)
Less: Series A Preferred Stock deemed dividend		—			(2,026	)
Net loss available to common shareholders	$	(9,689	)	$	(8,965	)
Weighted average shares of common stock outstanding		20,501,224			8,631,668
Less: Weighted-average shares of unvested common stock		—			(2,188	)
Total weighted-average shares used in computing net loss per share attributed to common stockholders		20,501,224			8,629,480
Basic and diluted loss per share	$	(0.47	)	$	(1.04	)

Because we reported a net loss for the years ended December 31, 2014 and 2013, all potentially dilutive shares of common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. As of December 31, 2014, none of the outstanding warrants were in-the-money and no material outstanding stock options were in-the-money; therefore, they would have been excluded from our weighted-average diluted earnings per share calculation. Such potentially dilutive shares of common stock consist of the following:

	Years Ended December 31,
	2014		2013
Potentially dilutive securities, excluded:
Outstanding stock options		1,068,515		843,442
Unvested restricted stock units		471,029		419,000
Warrants to purchase common stock		9,371,002		8,147,484
		10,910,546		9,409,926

Equity Financings and Warrants	12 Months Ended
Equity Financings and Warrants	Dec. 31, 2014
Equity [Abstract]
Equity Financings and Warrants	(7) Equity Financings and Warrants 2013 Equity Financings Private Investment in Public Equity (PIPE) Transactions On January 22, 2013, the Company entered into a Subscription Agreement (the “January 2013 Purchase Agreement”) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the January 2013 Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January 25, 2013. The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA’s common stock on the Nasdaq Capital Market on January 22, 2013. The Company filed a registration statement for the resale of the shares underlying the units sold in the private placement. That registration statement was declared effective by the Securities and Exchange Commission on February 14, 2013. In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a “variable rate transaction,” which means a transaction in which the Company issues or sells any convertible securities either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. Registered Direct Offering On January 31, 2013, the Company entered into a subscription agreement with certain institutional investors (the “Investors”) in connection with its Registered Direct public offering, pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fees and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the offering closed on February 4, 2013. The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA’s common stock on the Nasdaq Capital Market on January 31, 2013. The Offering was effected as a takedown of the Company’s Registration Statement on Form S-3, as amended, which became effective on April 4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 1, 2013. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise. Public Offering On June 4, 2013, the Company sold shares of its Series A Convertible Preferred Stock (Preferred Stock) and warrants to purchase common stock in a public offering for aggregate gross proceeds of $20.0 million. The Company issued 125,000 shares of Preferred Stock and warrants to purchase up to 6,250,000 shares of common stock at a purchase price of $160 per share of Preferred Stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by the Company, were approximately $17.9 million. ARCA’s Director and Chief Executive Officer participated in the offering, purchasing 781 shares of Preferred Stock and warrants to purchase 39,050 shares of common stock. Each share of Preferred Stock was convertible into 100 shares of the Company’s common stock at any time at the option of the holder. Each share of Preferred Stock had a liquidation preference of $.001 per share. The shares of Preferred Stock had no preferential dividends or redemption rights, and no voting rights except as required by law. During 2013, all 125,000 of the shares of the Preferred Stock were converted into 12,500,000 shares of ARCA common stock. Each purchaser in the offering was issued a warrant to purchase 50 shares of the Company’s common stock for each share of Preferred Stock purchased. The warrants have an exercise price of $1.60 per share, will expire on the five year anniversary of the date of issuance, and were exercisable immediately upon issuance, provided that the holder will be prohibited from exercising the warrants if, as a result of such exercise, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding. The securities were sold pursuant to a placement agreement and have been registered under the Securities Act of 1933 pursuant to the Company’s Registration Statement on Form S-1, as amended (No.333-187508), which was declared effective by the Securities and Exchange Commission on May 29, 2013, and the Preferred Stock and Warrants were offered and sold pursuant to a prospectus dated May 30, 2013. In connection with the Preferred Stock financing, the Company recorded a non-cash dividend of approximately $2.0 million to recognize the intrinsic value of the embedded beneficial conversion feature. Typically, such a deemed dividend would be represented as a reduction in a company’s retained earnings and an increase in additional paid in capital in recognition of the reapportionment of common shareholder value to the preferred stock purchasers. However, since ARCA has an accumulated deficit, the deemed dividend is recognized by a reapportionment of additional paid in capital from common shareholders to additional paid in capital of preferred stock purchasers, which are combined in the Company’s statement of stockholders’ equity. 2014 Equity Financing Registered Direct Offering On February 3, 2014, the Company agreed to sell to certain investors an aggregate of 5,116,228 shares of the Company’s common stock and warrants to purchase an aggregate of 1,279,057 shares of the Company’s common stock at a purchase price of $1.70 per share of Common Stock, for aggregate gross proceeds of approximately $8.7 million, before deducting placement agent fees and other offering related expenses. The offering closed on February 7, 2014, and the net proceeds to the Company were approximately $7.9 million. The common stock and warrants were sold in combination consisting of one share of common stock and a warrant to purchase 0.25 shares of common stock. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $2.125 per share, equal to 125% of the closing bid price of ARCA’s common stock on the Nasdaq Capital Market on February 3, 2014. The offering was effected as a takedown off the Company’s Registration Statement on Form S-3, as amended, which became effective on April 4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 4, 2014. The warrants provide for cashless exercise and settlement in unregistered shares if there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the shares of common stock underlying the warrants at the time of exercise. Warrants As of December 31, 2014, warrants to purchase 9,371,002 shares of common stock were outstanding at exercise prices ranging from $1.60 to $116.89, with a weighted average exercise price per share of $2.31. These warrants, which were granted as part of various financing and business agreements, expire at various times between April 2016 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model.

Share-based Compensation

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Share-based Compensation

(8) Share-based Compensation

Stock Plans

The Company’s equity incentive plan, the 2013 Equity Incentive Plan (the Equity Plan), was approved by stockholders on September 17, 2013. The maximum number of shares issuable under this plan is 2,250,000 shares.

The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December 31, 2014, options and awards for 1,437,477 shares were outstanding under the Equity Plan, and 672,852 shares were reserved for future awards.

In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of three to four years from the date of grant and have a maximum term of ten years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.

In conjunction with the adoption of the Equity Plan, the Company discontinued grants under its previous plan, the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the 2004 Plan), effective September 17, 2013. The 2004 Plan expired in 2014; however, options outstanding under the 2004 plan will continue to vest according to the original terms of each grant. As of December 31, 2014, options to purchase 59,776 shares with a weighted average exercise price of $15.10 per share were outstanding under this plan. Other stock plans that were assumed by ARCA in the Merger still have options outstanding that will continue to vest according to the original terms of each grant, but no new options can be granted under these plans, as the plans have expired. As of December 31, 2014, options to purchase 42,291 shares with a weighted average exercise price of $17.78 were outstanding under these plans.

The Company granted options and awards for 420,279 and 1,160,535 shares of common stock in the years ended December 31, 2014 and 2013, respectively. The fair values of the majority of employee stock options granted in the years ended December 31, 2014 and 2013 were estimated at the date of grant using the Black-Scholes model with the following assumptions and had the following estimated weighted average grant date fair value per share:

	Years Ended December 31,
	2014			2013
Expected term	5.9 years			5.8 years
Expected volatility		94	%		96	%
Risk-free interest rate		1.53	%		1.62	%
Expected dividend yield		0	%		0	%
Weighted-average grant date fair value per share	$	1.37		$	1.05

A summary of ARCA’s stock option and stock award activities for the years ended December 31, 2014 and 2013, and related information as of December 31, 2014, is as follows:

	Years Ended December 31,
	2014					2013
	Number of Options			Weighted Average Exercise Price		Number of Options			Weighted Average Exercise Price
Options outstanding, beginning of period		843,442		$	3.76		144,019		$	18.28
Granted		228,579			1.81		741,535			1.38
Exercised		—			—		—			—
Forfeited and cancelled		(3,506	)		140.67		(42,112	)		11.62
Options outstanding, end of period		1,068,515		$	2.89		843,442		$	3.76
Options exercisable, end of period		494,291		$	4.38		194,550		$	11.14
Options vested and expected to vest		1,066,712		$	2.89

The total intrinsic value of options exercised for the years ended December 31, 2014 and 2013 was $0 and $0, respectively. As of December 31, 2014, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $633,000 which is expected to be recognized over a weighted average period of 2.2 years. The Company recognizes compensation costs for its share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures.

The following table summarizes information about stock options outstanding and exercisable as of December 31, 2014:

					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number Outstanding		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.36	—	$	1.33		29,933		9.75	$	1.05		704	$	1.08
	1.38	—		1.38		727,869		8.47		1.38		329,189		1.38
	1.40	—		1.95		212,495		9.11		1.89		70,410		1.84
	1.96	—		22.98		82,300		4.44		13.68		78,070		13.55
	22.99	—		33.42		15,918		3.74		32.87		15,918		32.87
						1,068,515		8.25	$	2.89		494,291	$	4.38

Restricted Stock Units

The Company began granting restricted stock units (RSUs) to employees during 2013 in conjunction with the adoption of its 2013 Equity Incentive Plan. The fair value of RSU awards is the closing price of the Company’s common stock on the date of grant and is recognized as compensation expense on a straight-line basis over the respective vesting period. The stock awards granted have a requisite service period of three or four years with annual vesting on the grant anniversary date.

A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:

	Years Ended December 31,
	2014					2013
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares		Weighted Average Grant Date Fair Value
Restricted stock units outstanding, beginning of period		419,000		$	1.39		—	$	—
Granted		191,700			1.95		419,000		1.39
Vested and released		(139,671	)		1.39		—		—
Forfeited and cancelled	—			—		—		—
Restricted stock units outstanding, end of period		471,029		$	1.62		419,000	$	1.39

As of December 31, 2014, the total unrecognized compensation cost related to unvested stock awards was approximately $629,000. This cost will be recognized on a straight-line basis over the next 2.4 years and will be adjusted for estimated forfeitures.

Non-cash Stock-based Compensation

For the years ended December 31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):

	December 31,
	2014		2013
Research and development	$	158	$	77
General and administrative	$	489	$	206
Total	$	647	$	283

Stock-based compensation expense related to non-employees was negligible in 2014 and 2013. ARCA did not recognize any tax benefit related to employee stock-based compensation cost as a result of the full valuation allowance on its net deferred tax assets.

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

(10) Income Taxes

Effective June 1, 2005, the Company changed from an S-Corporation to a C-Corporation. As an S-Corporation, the net operating loss carryforwards were distributed to the Company’s stockholders; such amounts were not significant. Since June 2005 through December 31, 2014, for federal income tax purposes, the Company has net operating loss carryforwards of approximately $113.7 million, and approximately $991,000 of research and development credits that may be used to offset future taxable income. The net operating loss carryforwards will expire beginning 2025 through 2034. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company’s net operating loss carryforwards may be limited.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to the Company’s history of operating losses, management is unable to conclude that it is more likely than not that the Company will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax asset of approximately $44.5 million at December 31, 2014, reflecting a decrease of approximately $0.4 million from December 31, 2013. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December 31, 2014 the Company has not performed an Internal Revenue Code Section 382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.

Income tax benefit attributable to our loss from operations before income taxes differs from the amounts computed by applying the U.S. federal statutory income tax rate of 34% for 2014 and 35% for 2013, as a result of the following (in thousands):

	Year ended December 31,
	2014			2013
U.S. federal income tax benefit at statutory rates	$	(3,294	)	$	(2,429	)
State income tax benefit, net of federal benefit		(296	)		(209	)
Research and experimentation credits		(171	)		(133	)
Change in tax rate		1,041			—
Deferred tax asset adjustment		2,907			—
Other		178			184
Change in valuation allowance		(365	)		2,587
	$	—		$	—

Without regard to the deferred tax liability on the impaired IPR&D, the Company has had no provision for income taxes since inception due to its S-corporation status and its subsequent net operating losses.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of the Company’s net deferred tax assets consisted of the following (in thousands):

	Year ended December 31,
	2014			2013
Deferred tax assets:
Current deferred tax assets:
Vacation accrual	$	25		$	27
Total current deferred tax assets		25			27
Valuation allowance		(25	)		(27	)
Net current deferred tax assets	$	—		$	—

Noncurrent deferred tax assets:
Net operating loss carryforwards	$	42,135		$	39,799
Charitable contribution carryforwards		410			371
Research and experimentation credits		991			820
Capitalized intangibles		741			3,351
Stock based compensation		158			454
Depreciation and amortization		2			5
Other		—			—
Total noncurrent deferred tax assets		44,437			44,800
Valuation allowance		(44,437	)		(44,800	)
Net noncurrent deferred tax assets	$	—		$	—

Deferred tax liabilities:
Current deferred tax liabilities	$	—		$	—
Noncurrent deferred tax liabilities		—			—
Net deferred tax liabilities	$	—		$	—
Net noncurrent deferred tax assets	$	—		$	—

Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. Thus, the Company’s open tax years extend back to 2009. The Company believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on the Company’s financial condition, result of operations, or cash flow. For the years ended December 31, 2014 and 2013, the Company has no reserve for uncertain tax positions. The Company does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve months. In the event the Company concludes it is subject to interest or penalties arising from uncertain tax positions, the Company will record interest and penalties as a component of other income and expense. No material amounts of interest or penalties were recognized in the financial statements for the years ended December 31, 2014 and 2013.

The Company and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Description of Business

Risks, Liquidity and Going Concern

Liquidity and Going Concern

The Company’s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:

·	progress of GENETIC-AF, including enrollment and any data that may become available;

·	the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro;

·	the market price of the Company’s stock and the availability and cost of additional equity capital;

·	the Company’s ability to retain the listing of its common stock on the Nasdaq Capital Market;

·	general economic and industry conditions affecting the availability and cost of capital;

·	the Company’s ability to control costs associated with its operations;

·	the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and

·	the terms and conditions of the Company’s existing collaborative and licensing agreements.

Reverse Stock Split

Basis of Presentation

Recent Accounting Pronouncements

Accounting Estimates in the Preparation of Financial Statements

Cash Equivalents

The Company classifies all cash equivalents as available-for-sale securities, and records investments at fair value.

Concentrations of Credit Risk

Property and Equipment

Accrued Expenses

Segments

The Company operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.

Research and Development

Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.

Stock-Based Compensation

Income Taxes

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Summary of Basic and Diluted Loss Per Share

A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows:

	Years Ended December 31,
	2014			2013
(In thousands, except shares and per share data)
Net loss	$	(9,689	)	$	(6,939	)
Less: Series A Preferred Stock deemed dividend		—			(2,026	)
Net loss available to common shareholders	$	(9,689	)	$	(8,965	)
Weighted average shares of common stock outstanding		20,501,224			8,631,668
Less: Weighted-average shares of unvested common stock		—			(2,188	)
Total weighted-average shares used in computing net loss per share attributed to common stockholders		20,501,224			8,629,480
Basic and diluted loss per share	$	(0.47	)	$	(1.04	)

Summary Of Potentially Dilutive Shares Of Common Stock

	Years Ended December 31,
	2014		2013
Potentially dilutive securities, excluded:
Outstanding stock options		1,068,515		843,442
Unvested restricted stock units		471,029		419,000
Warrants to purchase common stock		9,371,002		8,147,484
		10,910,546		9,409,926

Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Estimated Weighted Average Grant Date Fair Value per Share

	Years Ended December 31,
	2014			2013
Expected term	5.9 years			5.8 years
Expected volatility		94	%		96	%
Risk-free interest rate		1.53	%		1.62	%
Expected dividend yield		0	%		0	%
Weighted-average grant date fair value per share	$	1.37		$	1.05

Summary of Stock Option and Stock Award Activities

A summary of ARCA’s stock option and stock award activities for the years ended December 31, 2014 and 2013, and related information as of December 31, 2014, is as follows:

	Years Ended December 31,
	2014					2013
	Number of Options			Weighted Average Exercise Price		Number of Options			Weighted Average Exercise Price
Options outstanding, beginning of period		843,442		$	3.76		144,019		$	18.28
Granted		228,579			1.81		741,535			1.38
Exercised		—			—		—			—
Forfeited and cancelled		(3,506	)		140.67		(42,112	)		11.62
Options outstanding, end of period		1,068,515		$	2.89		843,442		$	3.76
Options exercisable, end of period		494,291		$	4.38		194,550		$	11.14
Options vested and expected to vest		1,066,712		$	2.89

Summary of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable as of December 31, 2014:

					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number Outstanding		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	0.36	—	$	1.33		29,933		9.75	$	1.05		704	$	1.08
	1.38	—		1.38		727,869		8.47		1.38		329,189		1.38
	1.40	—		1.95		212,495		9.11		1.89		70,410		1.84
	1.96	—		22.98		82,300		4.44		13.68		78,070		13.55
	22.99	—		33.42		15,918		3.74		32.87		15,918		32.87
						1,068,515		8.25	$	2.89		494,291	$	4.38

Summary of RSU activity

A summary of RSU activity for the years ended December 31, 2014 and 2013 is presented below:

	Years Ended December 31,
	2014					2013
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares		Weighted Average Grant Date Fair Value
Restricted stock units outstanding, beginning of period		419,000		$	1.39		—	$	—
Granted		191,700			1.95		419,000		1.39
Vested and released		(139,671	)		1.39		—		—
Forfeited and cancelled	—			—		—		—
Restricted stock units outstanding, end of period		471,029		$	1.62		419,000	$	1.39

Non-Cash, Share-Based Compensation Expense

For the years ended December 31, 2014 and 2013, the Company recognized the following non-cash, share-based compensation expense (in thousands):

	December 31,
	2014		2013
Research and development	$	158	$	77
General and administrative	$	489	$	206
Total	$	647	$	283

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Tax Benefit Attributable to Our Loss from Operations

	Year ended December 31,
	2014			2013
U.S. federal income tax benefit at statutory rates	$	(3,294	)	$	(2,429	)
State income tax benefit, net of federal benefit		(296	)		(209	)
Research and experimentation credits		(171	)		(133	)
Change in tax rate		1,041			—
Deferred tax asset adjustment		2,907			—
Other		178			184
Change in valuation allowance		(365	)		2,587
	$	—		$	—

Net Deferred Tax Assets

	Year ended December 31,
	2014			2013
Deferred tax assets:
Current deferred tax assets:
Vacation accrual	$	25		$	27
Total current deferred tax assets		25			27
Valuation allowance		(25	)		(27	)
Net current deferred tax assets	$	—		$	—

Noncurrent deferred tax assets:
Net operating loss carryforwards	$	42,135		$	39,799
Charitable contribution carryforwards		410			371
Research and experimentation credits		991			820
Capitalized intangibles		741			3,351
Stock based compensation		158			454
Depreciation and amortization		2			5
Other		—			—
Total noncurrent deferred tax assets		44,437			44,800
Valuation allowance		(44,437	)		(44,800	)
Net noncurrent deferred tax assets	$	—		$	—

Deferred tax liabilities:
Current deferred tax liabilities	$	—		$	—
Noncurrent deferred tax liabilities		—			—
Net deferred tax liabilities	$	—		$	—
Net noncurrent deferred tax assets	$	—		$	—

The Company and Summary of Significant Accounting Policies (Details)					1 Months Ended	12 Months Ended
	Feb. 18, 2015 $ / shares	Feb. 03, 2014 USD ($)	Mar. 04, 2013	Jan. 31, 2013 USD ($)	Feb. 28, 2014 USD ($)	Dec. 31, 2014 USD ($) Patients Segment	Dec. 31, 2013 USD ($)
Company Basis of Presentation (Textual) [Abstract]
Date of completion of business combination with Nuvelo						Jan. 27, 2009
Revenues						$ 0
Fund raised through sale of convertible preferred and common stock							$ 19,300,000
Proceeds from the issuance of common stock						$ 9,038,000	$ 1,741,000
Notification for delisting of shares						On February 18, 2015, we received notification from NASDAQ of potential delisting of our shares from the NASDAQ Capital Market because the closing bid price of our common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30 days. NASDAQ rules provided us a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard would be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period.
Reverse stock split			1-for-6 reverse split
Concentrations of credit risk						$ 0
Number of segments \| Segment						1
Subsequent Event
Company Basis of Presentation (Textual) [Abstract]
Minimum closing bid price of common stock \| $ / shares	$ 1.00
Number of grace days provided by NASDAQ to meet continued listing standard	180 days
Registered Direct Offering
Company Basis of Presentation (Textual) [Abstract]
Proceeds from the issuance of common stock		$ 8,700,000		$ 730,000	$ 7,900,000
Phase 3 heart failure (HF) trial of Gencaro \| BEST Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients \| Patients						2,708
Phase 3 heart failure (HF) trial of Gencaro \| GENETIC-AF Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients company plans to enroll \| Patients						420
Phase Two B Heart Failure \| GENETIC-AF Trial
Company Basis of Presentation (Textual) [Abstract]
Number of patients company plans to enroll \| Patients						200
Original
Company Basis of Presentation (Textual) [Abstract]
Business combination with Nuvelo, date of agreement						Sep. 24, 2008
Amendment
Company Basis of Presentation (Textual) [Abstract]
Business combination with Nuvelo, date of agreement						Oct. 28, 2008

Summary of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net loss	$ (9,689)	$ (6,939)
Less: Deemed preferred stock dividend		(2,026)
Net loss available to common stockholders	$ (9,689)	$ (8,965)
Weighted average shares of common stock outstanding	20,501,224	8,631,668
Less: Weighted-average shares of unvested common stock		(2,188)
Total weighted-average shares used in computing net loss per share attributed to common stockholders	20,501,224	8,629,480
Basic and diluted loss per share	$ (0.47)	$ (1.04)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Equity Financings and Warrants (Details Textual) - USD ($)							1 Months Ended	12 Months Ended
	Feb. 07, 2014	Feb. 03, 2014	Jun. 04, 2013	Feb. 04, 2013	Jan. 31, 2013	Jan. 22, 2013	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013
Equity financings and warrants (Textual) [Abstract]
Common stock, shares issued								21,150,486	15,685,562
Proceeds from the issuance of common stock								$ 9,038,000	$ 1,741,000
Proceeds from the issuance of preferred stock									$ 20,000,000
Number of warrants outstanding								9,371,002
Class of warrant or rights expiration date earliest								2016-04
Class of warrant or rights expiration date latest								2020-01
Minimum
Equity financings and warrants (Textual) [Abstract]
Warrant price per share								$ 1.60
Maximum
Equity financings and warrants (Textual) [Abstract]
Warrant price per share								116.89
Weighted Average
Equity financings and warrants (Textual) [Abstract]
Warrant price per share								$ 2.31
Public Offering \| Preferred Stock
Equity financings and warrants (Textual) [Abstract]
Number of shares of preferred stock converted in to common stock									125,000
Public Offering \| Common stock
Equity financings and warrants (Textual) [Abstract]
Number of shares of common stock issued in conversion of preferred stock									12,500,000
Series A Convertible Preferred Stock \| Preferred Stock
Equity financings and warrants (Textual) [Abstract]
Issuance of Series A convertible preferred stock, net of offering costs, shares									125,000
Series A Convertible Preferred Stock \| Public Offering
Equity financings and warrants (Textual) [Abstract]
Warrants available to purchase additional commons shares			6,250,000
Warrant coverage ratio			50
Purchase price for common stock unit			$ 160
Warrants were exercisable upon issuance, expiry year			5 years
Warrant price per share			$ 1.60
Proceeds from the issuance of common stock			$ 17,900,000
Issuance of Series A convertible preferred stock, net of offering costs, shares			125,000
Proceeds from the issuance of preferred stock			$ 20,000,000
Common stock shares issued upon conversion of each share of convertible preferred stock			100
Preferred stock liquidation preference per share			$ 0.001
Percentage of total number of shares of common stock then issued and outstanding limit on beneficial ownership			9.99%
Intrinsic value of embedded beneficial conversion feature			$ 2,000,000
Director and Chief Executive Officer \| Public Offering
Equity financings and warrants (Textual) [Abstract]
Warrants available to purchase additional commons shares			39,050
Preferred Stock Purchased by Officer			781
PIPE Transaction
Equity financings and warrants (Textual) [Abstract]
Common stock, shares issued						356,430
Warrants available to purchase additional commons shares						249,501
Aggregate gross proceeds						$ 1,000,000
Net proceeds from issuance of private placement						$ 805,000
Public Equity Offering Close Date								Jan. 25, 2013
Subscription agreement date								Jan. 22, 2013
Warrant coverage ratio						0.70
Purchase price for common stock unit						$ 2.81
Warrants were exercisable upon issuance, expiry year						7 years
Warrant price per share						$ 2.28
Closing bid price of the common stock						100.00%
Closing bid price date								Jan. 22, 2013
Registered Direct Offering
Equity financings and warrants (Textual) [Abstract]
Common stock, shares issued		5,116,228			164,636
Warrants available to purchase additional commons shares		1,279,057			65,855
Public Equity Offering Close Date					Feb. 04, 2013			Feb. 07, 2014
Warrant coverage ratio		0.25			0.40
Purchase price for common stock unit		$ 1.70			$ 4.43
Warrants were exercisable upon issuance, expiry year		5 years			5 years
Warrant price per share		$ 2.125			$ 4.13
Closing bid price of the common stock		125.00%
Closing bid price date								Feb. 03, 2014	Jan. 31, 2013
Proceeds from the issuance of common stock		$ 8,700,000			$ 730,000		$ 7,900,000
Proceeds from the issuance of common stock	$ 7,900,000			$ 616,000
Subscription agreement date					Jan. 31, 2013

Share-based Compensation (Details Textual) - USD ($)	12 Months Ended
Share-based Compensation (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Sep. 17, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares outstanding under Equity plan	1,068,515	843,442		144,019
Stock options award, expiration	10 years
Weighted Average exercise Price of Options Outstanding	$ 2.89	$ 3.76		$ 18.28
Total intrinsic value of options exercised	$ 0	$ 0
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation expense related to unvested options	$ 633,000
Maturity period of weighted average period of compensation expenses	2 years 2 months 12 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maturity period of weighted average period of compensation expenses	2 years 4 months 24 days
Unrecognized compensation cost related to unvested stock awards	$ 629,000
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options award, vesting period	3 years
Percentage holding for stock options exercise price	10.00%
Minimum \| Incentive Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price of stock option	100.00%
Minimum \| Incentive Stock Option \| Stockholders
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price of stock option	110.00%
Minimum \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Units award, requisite service period	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options award, vesting period	4 years
Maximum \| Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Units award, requisite service period	4 years
2013 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future			2,250,000
Number of shares outstanding under Equity plan	1,437,477
Shares reserved for future	672,852
Options and awards granted	420,279	1,160,535
Two Thousand And Four Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares outstanding under Equity plan	59,776
Weighted Average exercise Price of Options Outstanding	$ 15.10
Other Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares outstanding under Equity plan	42,291
Weighted Average exercise Price of Options Outstanding	$ 17.78

Summary of Stock Option and Stock Award Activities (Details) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding beginning of period	843,442	144,019
Number of Options, Granted	228,579	741,535
Number of Options, Forfeited and cancelled	(3,506)	(42,112)
Options outstanding end of the period	1,068,515	843,442
Options exercisable, end of period, Number of Options	494,291	194,550
Options vested and expected to vest, Number of Options	1,066,712
Weighted Average exercise Price, Options Outstanding, Beginning of period	$ 3.76	$ 18.28
Weighted average exercise price, Granted	1.81	1.38
Weighted average exercise price, Forfeited and cancelled	140.67	11.62
Weighted Average exercise Price, Options Outstanding, end of period	2.89	3.76
Weighted average exercise price, Options exercisable, end of period	4.38	$ 11.14
Weighted Average exercise Price, Options vested and expected to vest, end of period	$ 2.89

Summary of Stock Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2014 $ / shares shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Outstanding number of Options \| shares	1,068,515
Outstanding Average Life	8 years 3 months
Outstanding Average Exercise Price	$ 2.89
Exercisable number of Options \| shares	494,291
Exercisable, Weighted Average Exercise Price	$ 4.38
$0.36-$1.33
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Price Range, Minimum	0.36
Price Range, Maximum	$ 1.33
Outstanding number of Options \| shares	29,933
Outstanding Average Life	9 years 9 months
Outstanding Average Exercise Price	$ 1.05
Exercisable number of Options \| shares	704
Exercisable, Weighted Average Exercise Price	$ 1.08
$1.38-$1.38
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Price Range, Minimum	1.38
Price Range, Maximum	$ 1.38
Outstanding number of Options \| shares	727,869
Outstanding Average Life	8 years 5 months 19 days
Outstanding Average Exercise Price	$ 1.38
Exercisable number of Options \| shares	329,189
Exercisable, Weighted Average Exercise Price	$ 1.38
$1.40-$1.95
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Price Range, Minimum	1.40
Price Range, Maximum	$ 1.95
Outstanding number of Options \| shares	212,495
Outstanding Average Life	9 years 1 month 10 days
Outstanding Average Exercise Price	$ 1.89
Exercisable number of Options \| shares	70,410
Exercisable, Weighted Average Exercise Price	$ 1.84
$1.96-$22.98
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Price Range, Minimum	1.96
Price Range, Maximum	$ 22.98
Outstanding number of Options \| shares	82,300
Outstanding Average Life	4 years 5 months 9 days
Outstanding Average Exercise Price	$ 13.68
Exercisable number of Options \| shares	78,070
Exercisable, Weighted Average Exercise Price	$ 13.55
$22.99-$33.42
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Price Range, Minimum	22.99
Price Range, Maximum	$ 33.42
Outstanding number of Options \| shares	15,918
Outstanding Average Life	3 years 8 months 27 days
Outstanding Average Exercise Price	$ 32.87
Exercisable number of Options \| shares	15,918
Exercisable, Weighted Average Exercise Price	$ 32.87

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes (Textual) [Abstract]
Net operating loss carryforwards	$ 113,700,000
Tax Credit Carryforward, Description	The net operating loss carryforwards will expire beginning 2025 through 2034.
Valuation allowance	$ 44,500,000
Decrease net deferred tax asset	$ 400,000
Federal statutory income tax rate	34.00%	35.00%
Provision for income taxes	$ 0	$ 0
Reserve for uncertain tax positions	0	0
Interest or penalties recognized	$ 0	$ 0
Open tax year	2009
Without Deferred Tax Liability On Impaired In Process Research And Development
Income Taxes (Textual) [Abstract]
Provision for income taxes	$ 0
Research Tax Credit Carryforward
Income Taxes (Textual) [Abstract]
Research and experimentation credits	$ 991,000
Operating loss carryforwards, limitations on use	Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company’s net operating loss carryforwards may be limited
Tax credit carryforward, limitations on use	Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by IRC Section 382. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of the Company’s net operating loss carryforwards may be limited
Earliest Tax Year
Income Taxes (Textual) [Abstract]
Operating loss carryforwards expiration year	2025
Latest Tax Year
Income Taxes (Textual) [Abstract]
Operating loss carryforwards expiration year	2034

Income Taxes - Income Tax Benefit Attributable to Our Loss from Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
U.S. federal income tax benefit at statutory rates	$ (3,294)	$ (2,429)
State income tax benefit, net of federal benefit	(296)	(209)
Research and experimentation credits	(171)	(133)
Change in tax rate	1,041
Deferred tax asset adjustment	2,907
Other	178	184
Change in valuation allowance	(365)	2,587
Total	$ 0	$ 0

Income Taxes - Net deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current deferred tax assets:
Vacation accrual	$ 25	$ 27
Total current deferred tax assets	25	27
Valuation allowance	(25)	(27)
Net current deferred tax assets	0	0
Noncurrent deferred tax assets:
Net operating loss carryforwards	42,135	39,799
Charitable contribution carryforwards	410	371
Research and experimentation credits	991	820
Capitalized intangibles	741	3,351
Stock based compensation	158	454
Depreciation and amortization	2	5
Total noncurrent deferred tax assets	44,437	44,800
Valuation allowance	(44,437)	(44,800)
Net noncurrent deferred tax assets	0	0
Deferred tax liabilities:
Net noncurrent deferred tax assets	$ 0	$ 0

Related Party Arrangements	12 Months Ended
Related Party Arrangements	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Arrangements	(5) Related Party Arrangements Transactions with the Company’s President and Chief Executive Officer The Company has entered into unrestricted research grants with its President and Chief Executive Officer’s academic research laboratory at the University of Colorado, or the Lab. Funding of any unrestricted research grants is contingent upon the Company’s financial condition, and can be deferred or terminated at the Company’s discretion. Total expense under these arrangements for the years ended December 31, 2014 and 2013 was $350,000 and $297,000 respectively.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	(9) Employee Benefit Plans The Company has a 401(k) plan and makes a matching contribution equal to 100% of the employee’s first 3% of the employee’s contributions and 50% of the employee’s next 2% of contributions. The Company adopted the plan in 2006 and contributed $108,000 and $70,000 for the years ended December 31, 2014 and 2013, respectively .

Net Loss Per Share (Details Textual)	12 Months Ended
Net Loss Per Share (Details Textual)	Dec. 31, 2014 shares
Equity Option
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities in-the-money	0
Warrant
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Securities in-the-money	0

Financial Instruments (Details) - USD ($)	12 Months Ended
Financial Instruments (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Financial Instruments (Additional Textual) [Abstract]
Transfers of assets between fair value hierarchy levels	$ 0	$ 0
Fair Value Measurements, Recurring \| Level 1 \| Money Market Funds
Financial Instruments (Textual) [Abstract]
Cash equivalents consisting of money market funds	15,300,000	$ 16,500,000
Fair Value Measurements, Recurring \| Fair Value, Inputs, Level 2
Financial Instruments (Additional Textual) [Abstract]
Fair value of assets	0
Fair value liabilities	0
Fair Value Measurements, Recurring \| Fair Value, Inputs, Level 3
Financial Instruments (Additional Textual) [Abstract]
Fair value of assets	0
Fair value liabilities	$ 0

Summary of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Property and Equipment, Gross	$ 418	$ 514
Accumulated depreciation and amortization	(382)	(485)
Property and equipment, net	$ 36	29
Computer Equipment
Property Plant And Equipment [Line Items]
Estimated Life	3 years
Property and Equipment, Gross	$ 97	99
Lab Equipment
Property Plant And Equipment [Line Items]
Estimated Life	5 years
Property and Equipment, Gross	$ 142	142
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Estimated Life	5 years
Property and Equipment, Gross	$ 89	89
Computer Software
Property Plant And Equipment [Line Items]
Estimated Life	3 years
Property and Equipment, Gross	$ 82	176
Leasehold Improvements
Property Plant And Equipment [Line Items]
Estimated Life	Lesser of useful life or life of the lease
Property and Equipment, Gross	$ 8	$ 8

Net Loss Per Share (Details 1) - shares	12 Months Ended
Net Loss Per Share (Details 1) - shares	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share Basic [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,910,546	9,409,926
Equity Option
Earnings Per Share Basic [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,068,515	843,442
Unvested restricted stock units
Earnings Per Share Basic [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	471,029	419,000
Warrant
Earnings Per Share Basic [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,371,002	8,147,484

Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 12	$ 26

Related Party Arrangements (Details) - USD ($)	12 Months Ended
Related Party Arrangements (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Chief Executive Officer \| Research Grants
Related Party Transaction [Line Items]
Total expense	$ 350,000	$ 297,000

Commitments and Contingencies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Aug. 01, 2013 ft²
Commitments and Contingencies (Textual) [Abstract]
Clinical research agreement with Duke University, termination notice period	90 days
Expected milestone payments due upon approval	$ 8,000
Another expected milestone payments due upon approval	$ 5,000
Minimum percentage of royalty obligation	12.50%
Maximum percentage of royalty obligation	25.00%
Product sales levels royalty	5.00%
Minimum percentage of range of royalties that can be bought down	12.50%
Maximum percentage of range of royalties that can be bought down	17.00%
Royalty buy down due period	6 months
Rent expense	$ 78	$ 63
Westminster, Colorado
Commitments and Contingencies (Textual) [Abstract]
Area of office facilities taken on lease \| ft²			5,300
Lease term	3 years
Lease expiry date	Sep. 30, 2016

Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2014 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2015	$ 80
2016	62
Total future minimum lease payments	$ 142

Estimated Weighted Average Grant Date Fair Value Per Share (Details) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Estimated weighted average grant date fair value per share
Expected term	5 years 10 months 24 days	5 years 9 months 18 days
Expected volatility	94.00%	96.00%
Risk-free interest rate	1.53%	1.62%
Expected dividend yield	0.00%	0.00%
Weighted-average grant date fair value per share	$ 1.37	$ 1.05

Summary of RSU Activity (Details) - $ / shares	12 Months Ended
Summary of RSU Activity (Details) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock Awards, Number of Shares
Restricted stock units outstanding, beginning of period	419,000
Granted	191,700	419,000
Vested and released	(139,671)
Restricted stock units outstanding, end of period	471,029	419,000
Restricted Stock Awards, Weighted Average Grant Date Fair Value
Restricted stock units outstanding, beginning of period	$ 1.39
Granted	1.95	$ 1.39
Vested and released	1.39
Restricted stock units outstanding, end of period	$ 1.62	$ 1.39

Non-Cash, Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total expenses	$ 647	$ 283
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total expenses	158	77
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total expenses	$ 489	$ 206

Employee Benefit Plans (Details) - USD ($)	12 Months Ended
Employee Benefit Plans (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution Plan Disclosure [Line Items]
Matching contribution	matching contribution equal to 100% of the employee’s first 3% of the employee’s contributions and 50% of the employee’s next 2% of contributions.
Company's contribution	$ 108,000	$ 70,000
First 3% of pay contributed
Defined Contribution Plan Disclosure [Line Items]
Benefit Plan, Percentage of Match	100.00%
Employer matching contribution percentage	3.00%
Next 2% of pay contributed
Defined Contribution Plan Disclosure [Line Items]
Benefit Plan, Percentage of Match	50.00%
Employer matching contribution percentage	2.00%